What is Noze?
Noze is at the forefront of digital scent detection technology, developing innovative solutions for enhanced disease detection and healthcare diagnostics. The company has engineered the world's first digital nose, designed to analyze health signals from breath and skin in real-world settings. Their primary product, DiagNoze, is currently in development and aims to transform medical diagnostics by enabling real-time health assessments via breath analysis at various points of care. Noze's technology targets critical sectors including healthcare, safety, and food integrity, with the ultimate goal of improving health outcomes and overall quality of life through the integration of scent detection into everyday applications.
How much funding has Noze raised?
Noze has raised a total of $5M across 1 funding round:
Private Equity
$5M
Private Equity (2024): $5M with participation from Bill & Melinda Gates Foundation
Key Investors in Noze
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation, established in 2000, is a prominent organization dedicated to supporting global health and poverty reduction initiatives, focusing on improving health outcomes and access to essential services.
What's next for Noze?
With the recent major enterprise-level funding and strategic investment, Noze is poised for significant expansion and product development. The substantial capital infusion is expected to accelerate the advancement of DiagNoze, bringing this groundbreaking digital nose technology closer to widespread clinical adoption. This strategic backing will likely enable Noze to scale its operations, enhance its research and development capabilities, and forge key partnerships within the healthcare and diagnostics industries. The company's focus on real-time, non-invasive health assessments through scent detection positions it as a key innovator in the future of medical diagnostics.
See full Noze company page
